Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A potentially registrational Phase 2 trial of WVE-N531 to evaluate functional dystrophin expression following 24 and 48 weeks of biweekly dosing of WVE-N531

Next Previous
Search
Trial Profile

A potentially registrational Phase 2 trial of WVE-N531 to evaluate functional dystrophin expression following 24 and 48 weeks of biweekly dosing of WVE-N531

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs WVE-N531 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Acronyms FORWARD-53
  • Sponsors WaVe life Sciences

Most Recent Events

  • 13 Jan 2025 According to a Wave Life Sciences media release, study is ongoing with all patients have elected to continue treatment in the planned extension portion of the study with monthly doses of WVE-N531.
  • 12 Nov 2024 According to a Wave Life Sciences media release, company expect feedback on a pathway to accelerated approval from regulators, as well as the complete 48-week FORWARD-53 data, in 1Q 2025
  • 01 Oct 2024 According to a Wave Life Sciences media release, company expects data from the complete FORWARD-53 study in the first quarter of 2025 and to receive feedback from regulators on a pathway to accelerated approval.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top